{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:49:26Z","timestamp":1791618566969,"version":"4.3.4"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.athoracsur.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:01:33Z","timestamp":1769695293000},"page":"774-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Direct Oral Anticoagulants in Adult Patients Undergoing Cardiac Surgery: A Joint Consensus Statement by the Society of Cardiovascular Anesthesiologists and The Society of Thoracic Surgeons"],"prefix":"10.1016","volume":"121","author":[{"given":"Ashley N.","family":"Budd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos D.","family":"Kertai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz C.","family":"Wyler von Ballmoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamrouz","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Shore-Lesserson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mazzeffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman M.","family":"Sniecinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi A.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bolliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Ural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Upchurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Rozental","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline B.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Klick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lobner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia B.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib4","article-title":"Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation","volume":"2014","author":"Salazar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17474086.2016.1135046","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation","volume":"9","author":"Ghadimi","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1161\/CIR.0000000000001285","article-title":"2024 AHA\/ACC\/ACS\/ ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/ American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezae355","article-title":"2024 EACTS guidelines on perioperative medication in adult cardiac surgery","volume":"67","author":"Jeppsson","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1053\/j.jvca.2022.02.034","article-title":"A new tool in the management of direct-acting oral anticoagulants in emergency cardiac surgery","volume":"36","author":"Bolliger","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1213\/ANE.0000000000006619","article-title":"Development and publication of clinical practice parameters, reviews, and meta-analyses: a report from the Society of Cardiovascular Anesthesiologists Presidential Task Force","volume":"138","author":"Kertai","year":"2024","journal-title":"Anesth Analg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.athoracsur.2017.01.020","article-title":"The American Association for Thoracic Surgery\/Society of Thoracic Surgeons position statement on developing clinical practice documents","volume":"103","author":"Bakaeen","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jocs.16027","article-title":"Emergency cardiac surgery in patients on oral anticoagulants and antiplatelet medications","volume":"37","author":"Akhrass","year":"2022","journal-title":"J Card Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1053\/j.jvca.2022.07.016","article-title":"Perioperative management of direct oral anticoagulants in cardiac surgery: practice recommendations based on current evidence","volume":"36","author":"Budd","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.21037\/jtd-22-428","article-title":"Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery\u2014a systematic review","volume":"14","author":"Matejic-Spasic","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezad340","article-title":"Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice","volume":"64","author":"Heuts","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.jvca.2017.06.026","article-title":"2017 EACTS\/EACTA guidelines on patient blood management for adult cardiac surgery","volume":"32","author":"Boer","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib20","first-page":"56","article-title":"High insurance rates prompt self-insurance","volume":"61","author":"Powills","year":"1987","journal-title":"Hospitals"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s40140-021-00511-z","article-title":"Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update","volume":"12","author":"Moster","year":"2022","journal-title":"Curr Anesthesiol Rep"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1053\/j.jvca.2022.09.003","article-title":"The effect of direct oral anticoagulants on outcomes after urgent or emergent cardiac surgery","volume":"36","author":"Hecht","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jth.13305","article-title":"Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery","volume":"14","author":"Spyropoulos","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2014-08-595496","article-title":"Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures","volume":"124","author":"Garcia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.athoracsur.2017.11.066","article-title":"Bleeding complications after use of novel oral anticoagulants in patients undergoing cardiac surgery","volume":"105","author":"Hassan","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-Xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth Analg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00365513.2018.1522664","article-title":"Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays","volume":"78","author":"Hillarp","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ijlh.13159","article-title":"DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban and rivaroxaban-treated patients from the START-Register","volume":"42","author":"Cini","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15563650.2020.1743846","article-title":"Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis","volume":"58","author":"Athavale","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/anae.14425","article-title":"International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery","volume":"73","author":"Erdoes","year":"2018","journal-title":"Anaesthesia"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology Recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jtcvs.2019.11.119","article-title":"Direct oral anticoagulants and cardiac surgery: a descriptive study of preoperative management and postoperative outcomes","volume":"161","author":"Fox","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2026.01.005_bib39","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ejcts\/ezab389","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"60","author":"Vahanian","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib41","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/jth.15415","article-title":"Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF Registry","volume":"19","author":"Cools","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial","volume":"113","author":"Douketis","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13054-015-0930-9","article-title":"Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants","volume":"19","author":"Faraoni","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3936","article-title":"Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial","volume":"4","author":"Karkouti","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamasurg.2022.2235","article-title":"Prothrombin complex concentrate vs plasma for post-cardiopulmonary bypass coagulopathy and bleeding: a randomized clinical trial","volume":"157","author":"Smith","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091381","article-title":"Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trial","volume":"14","author":"Karkouti","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/MBC.0b013e3283401465","article-title":"Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies","volume":"21","author":"Chowdary","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study","volume":"15","author":"Song","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12245-018-0215-6","article-title":"The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review","volume":"11","author":"Hoffman","year":"2018","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jcem-39-5-965","article-title":"Effects of pH and enzyme inhibitors on apparent generation of angiotensin I in human plasma","volume":"39","author":"Oparil","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low-versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor-associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2021","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcrc.2018.08.031","article-title":"Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals","volume":"48","author":"Santibanez","year":"2018","journal-title":"J Crit Care"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib56","first-page":"2637","article-title":"Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis","volume":"25","author":"Luo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib58","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","article-title":"Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022","volume":"40","author":"Kietaibl","year":"2023","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib59","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib60","series-title":"ANDEXXA (coagulation factor Xa [recombinant], inactivated-zhzo) [prescribing information]","year":"2024"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib61","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib62","article-title":"Heparin insensitivity and thrombotic risk associated with sequential uses of prothrombin complex concentrate and andexanet alfa for apixaban reversal during acute type A aortic dissection repair: a case report","volume":"16","author":"Brenner","year":"2022","journal-title":"A A Pract"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib63","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bja.2024.02.027","article-title":"Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro","volume":"132","author":"Mishima","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib64","first-page":"390","article-title":"Difficult intraoperative heparinization following andexanet alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezad100","article-title":"Andexanet alfa in acute aortic syndrome: first UK experience","volume":"63","author":"Al-Attar","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib66","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood-2019-125955","article-title":"Administration of andexanet alfa for direct factor Xa inhibitor reversal precludes therapeutic heparinization for cardiopulmonary bypass","volume":"124","author":"Thalji","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report","volume":"13","author":"Flaherty","year":"2019","journal-title":"A A Pract"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib68","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1053\/j.jvca.2023.12.001","article-title":"Cardiopulmonary bypass circuit obstruction and urgent replacement after the administration of andexanet alfa","volume":"38","author":"Nozumi","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib69","article-title":"2024 EACTS\/ EACTAIC guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP","volume":"67","author":"Casselman","year":"2024","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib70","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12055-021-01183-4","article-title":"The effect of hemoadsorption on rivaroxaban blood plasma concentration in emergency cardiac surgery","volume":"37","author":"Kruger","year":"2021","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib71","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/j.athoracsur.2020.03.108","article-title":"Ticagrelor and rivaroxaban elimination with cytosorb adsorber before urgent off-pump coronary bypass","volume":"110","author":"Mair","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib72","article-title":"Mechanistic considerations and pharmacokinetic implications on concomitant drug administration during CytoSorb therapy","volume":"4","author":"Scheier","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib74","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.3390\/jcm11195889","article-title":"Removal of apixaban during emergency cardiac surgery using hemoadsorption with a porous polymer bead sorbent","volume":"11","author":"Hassan","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib75","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40262-019-00857-y","article-title":"Effective removal of dabigatran by idarucizumab or hemodialysis: a physiologically based pharmacokinetic modeling analysis","volume":"59","author":"Fuhr","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib76","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib77","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/asheducation-2014.1.514","article-title":"What is the role of hemodialysis for dabigatran-associated major bleeding?","volume":"2014","author":"Kim","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib79","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1097\/SLA.0000000000003638","article-title":"Dabigatran reversal with idarucizumab in patients requiring urgent surgery: a subanalysis of the RE-VERSE AD study","volume":"274","author":"Levy","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-018-0300-5","article-title":"Idarucizumab for reversal of dabigatran: single-center real-world experience","volume":"19","author":"Sheikh-Taha","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib81","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2020-0186","article-title":"Idarucizumab (Praxbind((R> for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients","volume":"7","author":"Kalmanovich","year":"2021","journal-title":"Future Sci OA"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13748","article-title":"Use of idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain","volume":"33","author":"Crespo-Leiro","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib83","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1002\/ajh.24638","article-title":"Idarucizumab for urgent reversal of dabigatran for heart transplant: a case report","volume":"92","author":"Rimsans","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib84","article-title":"Use of idarucizumab to revert the anticoagulant effect of dabigatran in heart transplant surgery: an institutional experience","volume":"2020","author":"Herrera-Escandon","year":"2020","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1160\/th15-03-0266","article-title":"Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model","volume":"115","author":"Honickel","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib86","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/ALN.0000000000000863","article-title":"Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model","volume":"123","author":"Honickel","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib87","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib88","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab","volume":"113","author":"Honickel","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib90","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtcvs.2019.09.064","article-title":"Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing","volume":"160","author":"Beller","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5761\/atcs.oa.20-00213","article-title":"A comparative prospective observational study on the use of direct oral anticoagulants after cardiac surgery for the management of atrial fibrillation","volume":"27","author":"Sezai","year":"2021","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib92","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1111\/jocs.17203","article-title":"Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery","volume":"37","author":"Naik","year":"2022","journal-title":"J Card Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib93","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjsurg.2015.07.005","article-title":"Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis","volume":"210","author":"Anderson","year":"2015","journal-title":"Am J Surg"},{"key":"10.1016\/j.athoracsur.2026.01.005_bib94","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/europace\/euw208","article-title":"Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey","volume":"18","author":"Vranckx","year":"2016","journal-title":"Europace"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497526000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497526000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:31:39Z","timestamp":1774945899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497526000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003497526000822"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2026.01.005","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Direct Oral Anticoagulants in Adult Patients Undergoing Cardiac Surgery: A Joint Consensus Statement by the Society of Cardiovascular Anesthesiologists and The Society of Thoracic Surgeons","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Society of Thoracic Surgeons, International Anesthesia Research Society. Published by Elsevier Inc. on behalf of The Society of Thoracic Surgeons.","name":"copyright","label":"Copyright"}]}}